Immune modulation and microchimerism after unmodified versus leukoreduced allogeneic red blood cell transfusion in cancer patients: Results of a randomized study

Transfusion

Volumn 47, Issue 9, 2007, Pages 1691-1699

  Lapierre, Valérie ^a   Aupérin, Anne ^b   Robinet, Eric ^b   Ferrand, Christophe ^b   Oubouzar, Nadia ^b   Tramalloni, Dominique ^b   Saas, Philippe ^b   Debaene, Bertrand ^b   Lasser, Philippe ^b   Tiberghien, Pierre ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BIOLOGICAL MONITORING; CANCER; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ERYTHROCYTE TRANSFUSION; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOMODULATION; MALE; MICROCHIMERISM; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD TRANSFUSION, AUTOLOGOUS; CHIMERISM; CYTOKINES; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; LEUKOCYTES; MALE; MIDDLE AGED; NEOPLASMS; PHENOTYPE; SURVIVAL RATE;

EID: 34548130033     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01344.x     Document Type: Article

References (31)

1. Wang HY, Lee DA, Peng G, et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004 20 : 107 8.
2. Wang RF, Peng G, Wang HY. Regulatory T cells and toll-like receptors in tumor immunity. Semin Immunol 2006 18 : 136 42.
3. Enesel MB, Acalovschi I, Grosu V, et al. Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients. Anticancer Res 2005 25 : 4583 90.
4. Lapierre V, Aupérin A, Tiberghien P. Transfusion-induced immunomodulation following cancer surgery: fact or fiction? J Natl Cancer Inst 1998 90 : 573 80.
5. Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001 97 : 1180 95.
6. Blumberg N. Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt. Transfusion 2005 45 (2 Suppl 33S 9S.
7. Babcock GF, Alexander JW. The effects of blood transfusion on cytokine production by TH1 and TH2 lymphocytes in the mouse. Transplantation 1996 61 : 465 8.
8. Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med 2006 354 : 1166 76.
9. Utter GH, Owings JT, Lee TH, et al. Microchimerism in transfused trauma patients is associated with diminished donor-specific lymphocyte response. J Trauma 2005 58 : 925 31.
10. Lee TH, Paglieroni T, Utter GH, et al. High-level long-term white blood cell microchimerism after transfusion of leukoreduced blood components to patients resuscitated after severe traumatic injury. Transfusion 2005 45 : 1280 90.
11. van De Watering L, Hermans J, Witvliet M, Versteegh M, Brand A. HLA and RBC immunization after filtered and buffy coat-depleted blood transfusion in cardiac surgery: a randomized controlled trial. Transfusion 2003 43 : 765 71.
12. Vasconcelos E, Figueiredo AC, Seghatchian J. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and apheresis. Transfus Apher Sci 2003 29 : 13 6.
13. Gorochov G, Neumann AU, Kereveur A, et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med 1998 4 : 215 21.
14. Nollet F, Billiet J, Selleslag D, Criel A. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transplant 2001 28 : 511 8.
15. Crowder MJ, Hand DJ. Analysis of repeated measures. London : Chapman and Hall 1990.
16. Guide de définition des infections nosocomiales. Paris : CLIN Paris-Nord 1995.
17. Lee TH, Donegan EA, Slichter S, Busch MP. Transient increase in circulating donor leukocytes following allogeneic transfusions in immunocompetent transfusion recipients compatible with donor cell proliferation. Blood 1995 85 : 1207 11.
18. Lee TH, Paglieroni T, Ohto H, Holland PV, Busch MP. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. Blood 1999 93 : 3125 39.
19. Wang-Rodriguez J, Fry E, Fiebig E, et al. Immune response to blood transfusion in very-low-birthweight infants. Transfusion 2000 40 : 25 34.
20. Kruskall MS, Lee TH, Assmann SF, et al. Survival of transfused donor white blood cells in HIV-infected recipients. Blood 2001 98 : 272 9.
21. Sullivan DJ, Barton RG, Edelman LS, Shao Y, Nelson EW, Shelby J. Distinct effects of allogeneic blood transfusion on splenocyte cytokine production after hemorrhagic shock. Surg Res 1998 75 : 54 60.
22. Kirkley SA, Cowles J, Pellegrini VD Jr., Harris CM, Boyd AD, Blumberg N. Cytokine secretion after allogeneic or autologous blood transfusion. Lancet 1995 345 : 527.
23. Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells: they're back and critical for regulation of autoimmunity. Immunol Rev 2001 182 : 149 63.
24. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003 3 : 199 210.
25. Vieira PL, Christensen JR, Minaee S, et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol 2004 172 : 5986 93.
26. Matzinger P. The danger model: a renewed sense of self. Science 2002 296 : 301 5.
27. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001 13 : 114 9.
28. Busch OR, Hop WC, Hoynck van Papendrecht MA, Marquet RL, Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993 328 : 1372 6.
29. Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal surgery. J Clin Oncol 1994 12 : 1859 67.
30. Houbiers JG, Brand A, van de Watering LM, et al. Randomised controlled trial comparing transfusion of leukocyte-depleted or buffy-coat-depleted blood surgery for colorectal cancer. Lancet 1994 344 : 573 8.
31. Rios JA, Hambleton J, Viele M, et al. Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion 2006 46 : 1778 86.